Scienture Holdings, Inc. — 2023 Q2 10-Q Summary
Filing identity: The supplied filing is for TRxADE HEALTH, Inc. (ticker MEDS), not a registrant named Scienture Holdings, Inc. It covers the quarter and six months ended June 30, 2023; the financial statements are unaudited. Amounts below are U.S. dollars.
Business context and reporting period
TRxADE described itself as a technology-enabled healthcare platform, including a pharmaceutical marketplace, a licensed wholesaler and pharmacy, and telehealth operations. It reported about 14,100 registered platform users. The company had entered agreements to sell Community Specialty Pharmacy and Alliance Pharma Solutions; the filing describes these as planned strategic transactions, not completed sales as of June 30. It discontinued its SOSRx joint venture in February 2023.
Financial results and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $2.251 million | $3.279 million | $4.499 million | $6.519 million |
| Gross profit | $1.645 million | $1.171 million | $3.202 million | $2.507 million |
| Gross margin | 73% | 36% | 71% | 38% |
| Operating loss | $0.346 million | $1.103 million | $0.693 million | $2.072 million |
| Net loss attributable to TRxADE | $1.975 million | $1.084 million | $2.653 million | $2.044 million |
- Q2 loss included a $1.449 million expense from the change in fair value of warrant liabilities and $181,000 of interest expense. For the six-month period, the warrant-liability expense was $1.369 million and interest expense was $243,000.
- Cash at June 30 was $746,000, down from $1.111 million at December 31, 2022. Total assets were $3.745 million and total liabilities $5.040 million; shareholders’ equity was negative $1.295 million.
- Current liabilities were $4.263 million, producing a working-capital deficit of $2.168 million. Current liabilities included a $1.957 million warrant liability; this is a fair-value liability, not necessarily conventional borrowings.
- Cash used in operating activities was $603,000 for the first half, versus $2.179 million in the comparable 2022 period. Investing activities provided $281,000, including $420,000 associated with discontinued operations, while financing activities used $44,000.
- The filing reports $1.297 million of first-half cost of sales and $3.202 million gross profit. It also reports $138,875 invested in capitalized software during the period.
Material changes versus the prior comparable period
- Revenue declined 31% in Q2 and 31% for the first half. Management said marketplace platform sales increased 6%, while Trxade Prime revenue declined about 11%; the filing attributes the Prime decrease to lower sales.
- Gross margin rose substantially, to 73% in Q2 and 71% for the first half, from 36% and 38%, respectively. Management attributed the improvement to the marketplace’s higher contribution, which carries no cost of goods, and improved Prime margins.
- Operating expenses fell 12.5% in Q2 and 14.9% for the first half. Lower wages and general and administrative expenses were partly offset by higher technology, professional, and accounting and legal costs.
- Despite lower operating losses, reported net loss increased: the Q2 comparison was affected by the warrant-liability valuation expense and higher interest costs. The first-half result also included a $352,244 loss from discontinued operations.
Outlook, material events and risks
- Going concern: Management stated that limited cash, a $2.2 million working-capital deficit, accumulated deficit of $21.9 million, and need for further capital raise substantial doubt about the company’s ability to continue as a going concern. The filing says financing may be unavailable or dilutive, and that absent additional financing the company may be unable to meet funding needs over the next 12 months.
- Cash needs: The company estimated approximately $8 million of operating expenses and working-capital requirements for July 2023 through June 2024, primarily general and administrative costs. It said it expected to pursue revenue growth and strategic transactions for consumer-facing subsidiaries, with no assurance of positive cash flow or available financing.
- Receivables funding: A June 27, 2023 agreement provided for $1.25 million of funding in exchange for $1.8 million of future receivables, with a priority interest in Trxade Inc. receivables. The filing reports a 36% effective interest rate for contingent funding liabilities. It warns that default could require 100% of future receivables to be remitted and materially harm liquidity.
- Post-quarter merger: On July 31, 2023, the company completed its acquisition of Superlatus, Inc. Superlatus shareholders received 136,441 common shares and 306,855 Series B preferred shares, convertible at 100 common shares per preferred share. Management identified Superlatus as the accounting acquirer. A related proposed transfer of TRxADE operating subsidiaries to principal stockholders, in exchange for share surrenders, was conditioned on stockholder approval of preferred-stock conversion and the merger; the filing does not say that transfer had closed.
- Listing matters: The company regained Nasdaq’s minimum bid-price compliance in July after a 1-for-15 reverse stock split effective June 21. It had also received notice of a shortfall in publicly held shares. The filing states that the Superlatus merger brought stockholders’ equity above Nasdaq’s $2.5 million threshold; this was a post-period development, distinct from negative equity reported at June 30.
- Legal recoveries: A court settlement ordered Studebaker Defense Group to pay $550,000, but no payment had been received by the filing date. Payments under a separate $743,000 GSG settlement had stopped after January 2023; the company also reported no subsequent installments through the filing date.
- Controls: Management concluded disclosure controls were not effective at June 30, citing material weaknesses in written accounting/reporting policies and period-end financial reporting controls. Management said it was working to improve them.
Important facts for investors to verify
- Whether the company obtained sufficient financing to address the going-concern uncertainty and near-term cash requirements.
- Whether the Superlatus merger’s preferred-stock conversion, share issuances and related subsidiary stock-swap transactions were completed as contemplated, and the resulting ownership and dilution.
- Current Nasdaq compliance status, particularly the publicly held share requirement and ongoing equity requirements.
- Actual collections under the Studebaker and GSG settlements, and any related changes to receivables or earnings.
- Revenue and margin trends by business line, including the effect of any completed subsidiary sales or operational transfers.
- Terms, repayment progress and default status of future-receivables funding, and progress in remediating the disclosed control weaknesses.